menu
    • menu
    [{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoGenesis \/ EMD Serono","highestDevelopmentStatusID":"8","companyTruncated":"ImmunoGenesis \/ EMD Serono"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"ImmunoGenesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ ImmunoGenesis","highestDevelopmentStatusID":"8","companyTruncated":"ImmunoGenesis \/ ImmunoGenesis"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoGenesis \/ Molecular Templates","highestDevelopmentStatusID":"10","companyTruncated":"ImmunoGenesis \/ Molecular Templates"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Molecular Templates","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunoGenesis \/ Molecular Templates","highestDevelopmentStatusID":"10","companyTruncated":"ImmunoGenesis \/ Molecular Templates"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Agenus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Agenus","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Agenus"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Evofosfamide","moa":"||DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Funding","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Cancer Focus Fund","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Cancer Focus Fund"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Funding","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ImmunoGenesis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Undisclosed"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ PRA Health Sciences","highestDevelopmentStatusID":"8","companyTruncated":"ImmunoGenesis \/ PRA Health Sciences"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"PolyPid","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"IMGS-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoGenesis \/ ImmunoGenesis","highestDevelopmentStatusID":"4","companyTruncated":"ImmunoGenesis \/ ImmunoGenesis"}]

    Find Clinical Drug Pipeline Developments & Deals by ImmunoGenesis

    Menu

    ImmunoGenesis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ImmunoGenesis Doses First Patient in IMGS-101 Combo Trial for Solid Tumors

                            Details : IMGS-101 (evofosfamide) is a DNA inhibitor, which is being evaluated for the treatment of rmetastatic castration-resistant prostate cancer, pancreatic, & HPV(-) head & neck tumors.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 06, 2025

                            Lead Product(s) : Evofosfamide,Balstilimab,Zalifrelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Cast...

                            Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Agenus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

                            Details : Evofosfamide is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 20, 2025

                            Lead Product(s) : Evofosfamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Agenus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMGS-501

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : PolyPid

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PolyPid Collaborates with ImmunoGenesis On PLEX Tech for Cancer Immunotherapy

                            Details : The collaboration aims to address the challenges of IMGS-501. These potent STING agonists are Being evaluated for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : IMGS-501

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : PolyPid

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced...

                            Details : IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 28, 2023

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

                            Details : IMGS-001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 28, 2023

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Cancer Focus Fund

                            Deal Size : $4.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-0...

                            Details : The funding will be used to support the Phase 1a/1b clinical trial of ImmunoGenesis' lead candidate, IMGS-001, a dual-specific PD-L1/PD-L2 antibody designed to treat immune-excluded tumors, which are resistant to existing immunotherapy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 27, 2023

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Cancer Focus Fund

                            Deal Size : $4.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference

                            Details : IMGS-001, a PD-L1/PD-L2 dual-specific inhibitor with cytotoxic effector function. As first molecule to target PD-L2 in addition to PD-L1, has to shut down entire PD-1 pathway, providing superior blockade compared to other PD-1 or PD-L1 inhibitors.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 03, 2022

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) ...

                            Details : As the first molecule to target PD-L2 in addition to PD-L1, IMGS-001 has the potential to shut down the entire PD-1 pathway, potentially providing superior blockade compared to other PD-1 or PD-L1 inhibitors.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 15, 2021

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ImmunoGenesis

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Data from ImmunoGenesis' Lead Programs to be Presented at Society for Immunotherapy of Cancer (SITC) Conferenc...

                            Details : IMGS-001 dual-specific PD‑L1/PD‑L2 antibody designed with effector function to kill the immunosuppressive cells in the tumor microenvironment, re-envisions the starting point for cold tumor treatment.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 03, 2021

                            Lead Product(s) : IMGS-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth